Twist Bioscience FY26 Q3 adjusted EBITDA loss narrows to $(11.3) million; revenue rises 23% YoY to $118.4 million

• Twist Bioscience posted fiscal 3Q revenue of $118.4 million, up 23% year over year, beating guidance of $114 million-$115 million.
• Gross margin rose to 52.8%, up about 120 basis points sequentially from fiscal 2Q.
• Adjusted EBITDA loss narrowed to $11.3 million as the company said it is on track for breakeven in fiscal 4Q.
• DNA synthesis and protein solutions revenue climbed 39% year over year to $56.6 million, with about 369,000 genes shipped.
• NGS applications revenue increased 12% year over year to $61.8 million, with growth led by diagnostic customers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.